A phase Ib study of BEZ235, a dual inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR), in patients with advanced renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Papillary
  • Carcinoma, Renal Cell
  • Kidney Neoplasms

abstract

  • BEZ235 twice daily resulted in significant toxicity without objective responses; further development of this compound will not be pursued in this disease.

publication date

  • July 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4943396

Digital Object Identifier (DOI)

  • 10.1634/theoncologist.2016-0145

PubMed ID

  • 27286790

Additional Document Info

start page

  • 787

end page

  • 8

volume

  • 21

number

  • 7